1603584-72-0

Basic information

• Product Name: 4-bromo-5-chloro-2-fluorobenzaldehyde
• CAS NO: 1603584-72-0
• Molecular Weight: 237.456
• Mol File: 1603584-72-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-bromo-5-chloro-2-fluorobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-5-chloro-2-fluorobenzaldehyde(1603584-72-0)
• EPA Substance Registry System: 4-bromo-5-chloro-2-fluorobenzaldehyde(1603584-72-0)

Safety Data

• Hazardous Substances Data: 1603584-72-0(Hazardous Substances Data)

Upstream product

• 2106-05-0 5-chloro-2-fluoroaniline 
• 116369-24-5 4-bromo-5-chloro-2-fluoroaniline 
• 68-12-2 N,N-dimethyl-formamide 
• 120077-69-2 3-chloro4-bromo-benzaldehyde 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 201849-17-4 1-bromo-2-chloro-5-fluoro-4-methylbenzene 

Relevant articles and documents

Pd-Catalyzed, ortho C-H Methylation and Fluorination of Benzaldehydes Using Orthanilic Acids as Transient Directing Groups

The direct, Pd-catalyzed ortho C-H methylation and fluorination of benzaldehydes have been accomplished using commercially available orthanilic acids as transient directing groups. In these reactions, the 1-fluoro-2,4,6-trimethylpyridinium salts can be either a bystanding F+ oxidant or an electrophilic fluorinating reagent. An X-ray crystal structure of a benzaldehyde ortho C-H palladation intermediate was obtained using triphenylphosphine as the stabilizing ligand.

N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

The present invention is directed to substituted certain N-(heteroaryl)quinazolin-2-amine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein J, R3, and R4, are as defined herein, which are potent inhib

HETEROCYCLIC DERIVATIVES AND USE THEREOF

A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated with the activation of STAT3 protein.